Cancer Institute, USA. To promote RNA nanotechnology interests across the globe, the United Kingdom, a scientific hub in Europe, was chosen to host this meeting. The field of RNA nanotechnology is a multidisciplinary field that has participation from scientists of varying backgrounds. Therefore there is often a gap in shared knowledge between the disciplines. The primary goal of the conference was to engage in proactive discussions within a small group of recognized inter-disciplinary experts (in chemistry, biochemistry, structural biology, microbiology, cancer biology, cell biology, biophysics, pharmaceutical sciences, material sciences, nanotechnology, and engineering) on how RNA can be utilized as a nanomaterial to make substantial leaps in the nanobiotechnology frontier. Furthermore, the conference provided not only an educational platform to disseminate knowledge, but also promoted new collaborations between scientists in different subcategories of RNA nanotechnology to grow and expand the field. This report aims to summarize several key scientific breakthroughs and emerging cross-disciplinary approaches in the field based on the presentations and discussions, which can be grouped into five sub-themes as discussed in this report.
It is evident now that in the past few years the field of RNA nanotechnology (1-3) has expanded tremendously, bringing under its umbrella a large group of interdisciplinary sciences and researchers with different areas of expertise. The most recent RNA nanotechnology conference organized by the Fusion Conferences Limited was held August 1-4, 2016 in Wokefield Park, Berkshire, United Kingdom. This was the fourth meeting in the RNA Nanotechnology and Therapeutics conference series following the highly successful international meetings held in 2010 (Cleveland, OH, USA), 2013 (Lexington, KY, USA), and 2015 (Gordon Research Conferences, Ventura, CA, USA). The first meeting in Cleveland, nicely summarized by a review paper published in ACS Nano (4) , drew the attention to the growing field of RNA nanotechnology. The second successful and well-attended conference in Lexington (5) paved the way to organizing the follow up annual meetings that involved a broader range of scientists and experts with different research backgrounds. 2015 Gordon Research Conference had a great recognition with the discussed topics as outlined in the conference webpage. The most recent meeting in Berkshire was also chaired by Dr. Peixuan Guo (The Ohio State University, USA), who pioneered the field of RNA nanotechnology, and co-chaired by Drs. Eric Westhof (Université de Strasbourg, France), Xing-Jie Liang (National Center for Nanoscience and Technology, China), and Bruce Shapiro (National Institutes of Health/National
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Nanotechnologies relevant to RNA research
More and more disciplines and technologies address their potential deficiencies and find their specific applications and uses within the field of RNA nanotechnology. Dr. Xiyun Yan (Chinese Academy of Sciences, Beijing, China) discussed advances in developing next generation artificial enzymes -termed nanozymes that are ferromagnetic nanoparticles with intrinsic peroxidaselike activity. Several variants of nanozymes are being developed for cancer diagnosis, tumor therapy and nanobiotechnological applications. Dr. Francesca Storici (Georgia Institute of Technology, USA) shared her recent exciting discovery that RNA is recombinogenic and can serve as precise template for chromosomal double-strand break repair via homologous recombination in yeast. These basic biological findings provide new avenues for designing therapeutic RNAs for genome engineering. Dr. Rob DeLong (Kansas State University, USA) discussed the development of inorganic/RNA complexes using zinc oxide/poly I:C and zinc oxide/Torula yeast RNA as anti-cancer models for developing therapeutic strategies against melanoma and other solid tumors. Dr. Xing-Jie Liang discussed advancements in non-viral nanoparticle designs and methods for tuning the physiochemical properties (size, shape and surface charge) for delivery of RNAi therapeutics to diseased cells with high efficacy while reducing toxicity and side effects. 
